Disc Medicine (NASDAQ:IRON) CEO John Quisel Sells 33,000 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John Quisel sold 33,000 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $74.96, for a total transaction of $2,473,680.00. Following the completion of the sale, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at $16,945,757.44. This represents a 12.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Disc Medicine Stock Down 1.3%

Disc Medicine stock opened at $75.01 on Wednesday. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 1-year low of $40.00 and a 1-year high of $99.50. The firm’s fifty day simple moving average is $70.77 and its 200-day simple moving average is $69.96. The company has a market capitalization of $2.86 billion, a P/E ratio of -11.33 and a beta of 0.97.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). Sell-side analysts forecast that Disc Medicine, Inc. will post -6.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

Hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Disc Medicine by 22.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock worth $756,000 after purchasing an additional 2,807 shares during the last quarter. Millennium Management LLC increased its position in Disc Medicine by 1,277.1% in the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock worth $5,386,000 after buying an additional 100,620 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Disc Medicine by 3.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock worth $4,793,000 after buying an additional 3,454 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Disc Medicine by 18.0% during the second quarter. Legal & General Group Plc now owns 24,097 shares of the company’s stock worth $1,276,000 after buying an additional 3,682 shares during the last quarter. Finally, Invesco Ltd. boosted its position in shares of Disc Medicine by 21.6% in the second quarter. Invesco Ltd. now owns 16,817 shares of the company’s stock valued at $891,000 after acquiring an additional 2,983 shares during the period. 83.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IRON has been the topic of a number of analyst reports. Wedbush reissued an “outperform” rating and set a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Morgan Stanley boosted their target price on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and an average price target of $104.44.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.